Results of a policy with arm veins used as the first alternative to an unavailable ipsilateral greater saphenous vein for infrainguinal bypass

Hölzenbein, Thomas; Pomposelli, Frank B.; Miller, Arnold; Contreras, Mauricio; Gibbons, G. W.; Campbell, David R.; Freeman, Dorothy V.; LoGerfo, Frank W.

doi:10.1016/s0741-5214(05)80043-6

Cited by 119 publications

(85 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is consistent with previous reports, 29 including the experience reported from our institution. 30 The reasons for this difference are multiple and probably not related to any flaw in the intrinsic biology of arm veins. 31 The arm veins have often received previous venipunctures or cannulations, with resultant injury and scarring.…”

Section: Commentmentioning

confidence: 99%

Lower Extremity Revascularization in Diabetes

Akbari

Pomposelli²,

Gibbons³

et al. 2000

Arch Surg

104

View full text Add to dashboard Cite

Section: Commentmentioning

confidence: 99%

Lower Extremity Revascularization in Diabetes

Akbari

Pomposelli²,

Gibbons³

et al. 2000

Arch Surg

104

View full text Add to dashboard Cite

“…Evidence suggests that there is no difference in outcome between reversed and nonreversed long saphenous vein grafts 37 and that comparable patency can be obtained with arm vein. 38 Because arm vein grafts are often used in difficult repeat surgery, there may be a mistaken impression of poorer outcomes.…”

Section: Discussionmentioning

confidence: 99%

Is Duplex Surveillance of Value After Leg Vein Bypass Grafting?

et al. 2005

View full text Add to dashboard Cite

on Behalf of the VGST ParticipantsBackground-The purpose of this study was to assess the benefits of duplex compared with clinical vein graft surveillance in terms of amputation rates, quality of life, and healthcare costs in patients after femoropopliteal and femorocrural vein bypass grafts. Methods and Results-This was a multicenter, prospective, randomized, controlled trial. A total of 594 patients with a patent vein graft at 30 days after surgery were randomized to either a clinical or duplex follow-up program at 6 weeks, then 3, 6, 9, 12, and 18 months postoperatively. The clinical and duplex surveillance groups had similar amputation rates (7% for each group) and vascular mortality rates (3% versus 4%) over 18 months. More patients in the clinical group had vein graft stenosis at 18 months (19% versus 12%, Pϭ0.04), but primary patency, primary assisted patency, and secondary patency rates, respectively, were similar in the clinical group (69%, 76%, and 80%) and the duplex group (67%, 76%, and 79%). There were no apparent differences in health-related quality of life, but the average health service costs incurred by the duplex surveillance program were greater by £495 (95% CI £183 to £807) per patient. Conclusions-Intensive

show abstract

“…[1][2][3][4][5]10 Neointimal formation after bypass grafting or angioplasty involves a complex interaction between multiple growth factors that promote VSMC proliferation and migration. [10][11][12][13][14] Therefore, it appears unlikely that selective inhibition of a particular growth factor will completely prevent lesion formation.…”

Section: Discussionmentioning

confidence: 99%

“…1,2 While the neointimal hyperplasia that occurs in all vein grafts helps to achieve mechanical stability in these otherwise thin-walled conduits, it is believed that this neointima serves as the substrate for the development of atherosclerotic disease. Up to 50% of vein bypass grafts fail within a period of 10 years as a result of this occlusive disease, [3][4][5] whereas high patency rates are maintained for periods exceeding 15 years when arterial vessels without significant neointima are used as bypass grafts.…”

Section: Introductionmentioning

confidence: 99%

Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene

et al. 1998

View full text Add to dashboard Cite

The senescent cell-derived inhibitor (sdi)-1 (p21) protein heavy isoforms, adult type specific SM2 and embryonic has been identified as a downstream mediator of the tumor specific SMemb/NMHC-B, demonstrated expression of the suppressor p53 in the cell cycle regulation. In this study, adult phenotype of VSMCs in the neointima of sdi-1 genewe focused on the function of sdi-1 gene in inhibiting vastransfected vein grafts at 2 weeks after the operation, while cular smooth muscle cell (VSMC) proliferation after vein the neointima was predominantly composed of embryonic grafting in a rabbit model. To test the hypothesis, we transphenotype of VSMCs in the control grafts. Overall, these fected human sdi-1 gene by an intra-operative approach.results demonstrate that a single intraluminal incubation of Accompanied by markedly increased sdi-1 protein, the sighuman sdi-1 gene can result in a significant inhibition of nificant increase in PCNA-stained VSMCs in vein grafts neointimal formation after vein grafting, associated with was inhibited by transfection of sdi-1 gene. Moreover, at 2 phenotypic change of VSMCs from neonatal to adult type weeks after transfection, transfer of sdi-1 gene resulted in in a rabbit model. Inhibition of hyperplasia in a graft model a significant inhibition in neointimal formation, compared by transfection of sdi-1 gene may be due to the change in with control vector. Of importance, immunohistological VSMC phenotype from neonatal to adult, in addition to the studies determining the expression pattern of myosin inhibition of VSMC growth.

show abstract

Results of a policy with arm veins used as the first alternative to an unavailable ipsilateral greater saphenous vein for infrainguinal bypass

Cited by 119 publications

References 31 publications

Lower Extremity Revascularization in Diabetes

Lower Extremity Revascularization in Diabetes

Is Duplex Surveillance of Value After Leg Vein Bypass Grafting?

Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene

Contact Info

Product

Resources

About